Cathie Wood’s Ark Funds Built Up Big Stakes in Crispr Stock. The Stock Tumbled.

barrons logo

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit

  • Order Reprints

  • Print Article

Crispr Therapeutics stock was tumbled Wednesday after the results of an experimental treatment from the gene-based medicine specialist underwhelmed investors. 

That is bad news for high-profile investor Cathie Wood, whose Ark Investment Management recently bought shares in the biotech company for two of its actively managed exchange-traded funds (ETFs). 


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also
Back to top button